The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. The latest episode features Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology biological products and on providing CDMO services through its Scinai Bioservices business unit.
To begin the interview, Reichman discussed Scinai Immunotherapeutics’ business model.
“Scinai is developing its own innovative pipeline of biological therapeutic products based on a unique technology of VHH single domain antibodies originating from alpacas,” he said. “The antibodies are licensed from the Max Planck Institute and the University Medical Centre Göttingen, both in Germany. The two principal investigators with whom who we work are Professor Dirk Görlich and Professor Matthias Dobbelstein.”
Join IBN’s Carmel Fisher and Amir Reichman, CEO of Scinai Immunotherapeutics, to learn more about the company’s recent milestones.
To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
24/7 News: The Latest
The latest news in 4 minutes updated every hour, every day.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com